{"editorial":{"content_id":"deff77ce-e737-43fc-89fa-46dd69d8f99e","slug":"iii","content_type":"news","title":"巴西I/II类医疗器械注册改为电子申请，中资厂商准入提速","summary":"巴西Anvisa宣布国际医疗器械制造商（I/II类）注册可通过Solicita系统电子申请，简化纸质流程，加快产品准入，对在巴中资医疗器械企业是利好。","body":"巴西国家卫生监督局（Anvisa）近日宣布，国际医疗器械制造商（风险等级I和II类）的注册登记现已支持电子申请，企业可通过Solicita系统提交，主题代码为80326。此举取代了原有的纸质流程，旨在提高审批效率。对于在巴西市场销售中低风险医疗器械的中资企业而言，这意味着更快的准入通道和更低的行政成本。\n\nAnvisa此次将I类和II类医疗器械的国际制造商注册流程全面电子化，申请统一通过Solicita系统提交，并指定主题代码80326。底稿未明确具体生效日期，但该变更已正式公布，表明巴西监管机构正在加速行政流程数字化。I类和II类属于低至中等风险产品，包括手术器械、诊断设备等，此前纸质申请周期长、易出错，新系统有望缩短注册时间。\n\n对于在巴中资医疗器械企业，尤其是出口手术器械、医用耗材、诊断试剂等I/II类产品的厂商，这一变化直接降低了合规门槛。此前，纸质流程需邮寄文件、人工审核，周期常达数月；电子化后，文件提交和状态跟踪均可在线完成，减少了中间环节。底稿未提及对中资企业的具体影响，但通过简化注册流程，产品进入巴西市场的速度将加快，有助于中资企业更灵活地响应市场需求。相关企业应尽快熟悉Solicita系统操作，确保文件符合Anvisa要求，避免因格式问题延误申请。\n\nCBI解读：底稿显示Anvisa将电子申请范围扩展至国际制造商，这是巴西监管数字化趋势的一部分。CBI认为，此举不仅利好中资企业，也反映了巴西整体营商环境改善的迹象。但需注意，电子化并不等于审批标准放宽，Anvisa对技术文件、质量管理体系的要求不会降低。中资企业应借此机会优化内部合规流程，同时关注后续是否将电子申请扩展至III/IV类高风险产品。\n\n待观察：一是Anvisa是否公布电子申请的平均审批时长，以评估效率提升幅度；二是Solicita系统是否支持葡萄牙语以外的语言界面，方便非葡语企业操作；三是未来是否将电子申请范围扩大至III/IV类产品，这将影响更多中资企业。","why_it_matters":"巴西Anvisa将I/II类医疗器械注册改为电子申请，直接简化中资企业准入流程，加快产品进入巴西市场。","cbi_observation":"底稿显示Anvisa将电子申请范围扩展至国际制造商，这是巴西监管数字化的一部分。CBI认为，此举将缩短中资企业产品注册周期，但审批标准不会放松，企业应优化合规流程以充分利用政策红利。","direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["政策","合规","市场进入","br-health"],"content_level":"编辑整理","event_type":"监管变化","audience_tags":["在巴中资医疗器械企业","医疗器械出口商","合规负责人"],"event_location":"在巴西销售I/II类医疗器械的中资厂商，涉及手术器械、医用耗材、诊断试剂等。","verification_status":"unverified","published_at":"2026-08-15T11:00:40.512Z","display_date":"2026-08-15","source_published_at":null,"source_url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/cadastro-de-fabricantes-internacionais-de-dispositivos-medicos-risco-i-e-ii-agora-e-eletronico","source_name":"Anvisa","source_language":"pt","author_name":"Clara Lin","risk_level":"low","risk_flags":["regulatory_uncertainty"],"opportunity_flags":["market_entry_opportunity"],"trend_signals":["bilateral_trade_acceleration"]},"intelligence":{"intel_id":"3acfbff5-676a-420b-9448-90ba73e72dbe","version":1,"event_type":"政策发布","event_date":null,"main_entities":[{"name":"巴西国家卫生监督局（Anvisa）","role":"发布电子申请新规的监管机构","type":"regulator","country":"巴西","normalized_name":null},{"name":"Solicita系统","role":"接受电子申请的系统平台","type":"platform","country":"巴西","normalized_name":null},{"name":"I/II类医疗器械","role":"适用范围为低至中等风险器械","type":"product","country":"巴西","normalized_name":null},{"name":"在巴中资医疗器械企业","role":"受新规影响的利益相关方","type":"sector","country":"中国","normalized_name":null}],"main_action":"Anvisa将I/II类国际医疗器械注册改为电子申请，简化流程以加快准入。","key_numbers":[{"unit":"代码","label":"主题代码","value":80326}],"facts":[{"verified":true,"statement":"Anvisa宣布国际医疗器械制造商（风险等级I和II类）的注册登记支持电子申请。","source_excerpt":null},{"verified":true,"statement":"电子申请通过Solicita系统提交，主题代码为80326。","source_excerpt":null},{"verified":true,"statement":"新规取代了原有的纸质流程。","source_excerpt":null},{"verified":true,"statement":"底稿未明确具体生效日期。","source_excerpt":null}],"assessments":[{"statement":"该电子化流程将降低中资企业进入巴西市场的行政成本和时间。","confidence":"medium","basis_fact_index":null},{"statement":"电子化并不代表Anvisa对技术文件和质量管理体系的要求放宽。","confidence":"high","basis_fact_index":null}],"actions":[{"target":"both","priority":"high","description":"尽快熟悉Solicita系统操作，确保文件符合Anvisa格式要求。"},{"target":"both","priority":"normal","description":"持续关注Anvisa是否将电子申请扩展至III/IV类高风险产品。"}],"affected_audience":["在巴西销售中低风险医疗器械的中资企业","面向巴西出口手术器械、医用耗材、诊断试剂的中国厂商"],"risk_flags":["regulatory_uncertainty"],"opportunity_flags":["market_entry_opportunity"],"trend_signals":["bilateral_trade_acceleration"],"follow_up_needed":true,"follow_up_questions":["Anvisa是否公布电子申请的平均审批时长？","Solicita系统是否支持葡萄牙语以外的语言界面？","未来是否将电子申请范围扩大至III/IV类产品？"],"related_topics":["巴西医疗器械监管","Anvisa数字化审批","中资企业巴西准入"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-08-15T11:00:52.439Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/iii","api_url":"https://chinabrazilinsight.com/api/public/content/iii","markdown_url":"https://chinabrazilinsight.com/api/public/content/iii?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/iii?view=json","last_updated":"2026-08-15T11:00:52.475Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}